Advertisement

Angiogenesis

, 3:15 | Cite as

The urokinase plasminogen activator system in cancer: Implications for tumor angiogenesis and metastasis

  • Andrew P. Mazar
  • Jack Henkin
  • Ronald H. Goldfarb
Article

Abstract

Substantial evidence exists which implicates the urokinase plasminogen activator system [urokinase plasminogen activator (uPA), urokinase plasminogen activator receptor (uPAR) and plasminogen activator inhibitor-1 (PAI-1)] in the neo-vascularization, invasion and metastasis of many solid tumors. Clinical studies have demonstrated an association between high levels of expression of the components of this system in tumors and poor patient prognosis and outcome. Components of the uPA/uPAR system are differentially expressed or activated on motile cells including invading tumor cells and leukocytes, and migrating endothelial cells. In contrast, there is little or no expression on most normal, quiescent cells. Studies performed in vitro have demonstrated the regulation of the expression of uPA and uPAR by growth and differentiation factors as well as by oncogenes. In this review, we summarize recent findings on the role of the components of the uPA/uPAR system in angiogenesis, invasiveness and tumor metastasis. The activities of this system in endothelial and leukocyte cell biology and the relevance of these activities to angiogenesis and tumor metastasis will be considered. Recent experimental evidence obtained using inhibitors of uPA and uPAR has validated this system as a therapeutic target for the development of anti-angiogenic and anti-metastatic therapeutic agents. These studies, as well as additional therapeutic and diagnostic implications for uPAR targeting, will be discussed.

angiogenesis invasion metastasis PAI-1 plasminogen activator uPA uPAR 

References

  1. 1.
    Saksela O. Plasminogen activation and regulation of pericellular proteolysis. Biochim Biophys Acta 1985; 823: 35–65.PubMedGoogle Scholar
  2. 2.
    Wachtfogel YT, Abrams W, Kucich U et al. Fibronectin degradation products containing the cytoadhesive tetrapeptide stimulate neutrophil degranulation. J Clin Invest 1988; 81(5): 1310–6.PubMedGoogle Scholar
  3. 3.
    Sordat BC, Trân-Thang C. Laminin degradation by human colon carcinoma cells: A role for urinary and tissue plasminogen activators. Invasion Metastasis 1994; 14(1–6): 223–33.PubMedGoogle Scholar
  4. 4.
    Liotta LA, Goldfarb RH, Brundage R et al. Effect of plasminogen activator (urokinase), plasmin, thrombin on glycoprotein and collagenous components of basement membrane. Cancer Res 1981; 41: 4629–36.PubMedGoogle Scholar
  5. 5.
    Gaffney PJ. Fibrin (-ogen) interactions with plasmin. Haemostasis 1977; 6: 2–25.PubMedGoogle Scholar
  6. 6.
    Rick ME, Krizek DM. Platelets modulate the proteolysis of factor VIII:C protein by plasmin. Blood 1986; 67(6): 1649–54.PubMedGoogle Scholar
  7. 7.
    Lyons RM, Gentry LE, Purchio AF, Moses HL. Mechanism of activation of latent recombinant transforming growth factor β1 by plasmin. J Cell Biol 1990; 110: 1361–7.PubMedGoogle Scholar
  8. 8.
    Park JE, Keller GA, Ferrara N. The vascular endothelial growth factor (VEGF) isoforms: Differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell 1993; 4(12): 1317–26.PubMedGoogle Scholar
  9. 9.
    Remacle-Bonnet MM, Garrouste FL, Pommier GJ. Surface-bound plasmin induces selective proteolysis of insulin-like-growth-factor (IGF)-binding protein-4 (IGFBP-4) and promotes autocrine IGF-II bio-availability in human colon-carcinoma cells. Int J Cancer 1997; 72: 835–43.PubMedGoogle Scholar
  10. 10.
    Ginestra A, Monea S, Seghezzi G et al. Urokinase plasminogen activator and gelatinases are associated with membrane vesicles shed by human HT1080 fibrosarcoma cells. J Biol Chem 1997; 272(27): 17216–22.PubMedGoogle Scholar
  11. 11.
    Odekon LE, Blasi F, Rifkin DB. Requirement for receptor-bound urokinase in plasmin-dependent cellular conversion of latent TGF-β to TGF-β. J Cell Physiol 1994; 158: 398–407.PubMedGoogle Scholar
  12. 12.
    Mazzieri R, Masiero L, Zanetta L et al. Control of type IV collagenase activity by components of the urokinase-plasmin system: A regulatory mechanism with cell-bound reactants. EMBO J 1997; 16(9): 2319–32.PubMedGoogle Scholar
  13. 13.
    Murphy G, Atkinson S, Ward R et al. The role of plasminogen activators in the regulation of connective tissue metalloproteinases. Ann NY Acad Sci 1992; 667: 1–12.PubMedGoogle Scholar
  14. 14.
    Lee CD, Mann KG. Activation/inactivation of human factor V by plasmin. Blood 1989; 73: 185–190.PubMedGoogle Scholar
  15. 15.
    Higazi AAR, Barghouti II. Inactivation of human anaphylotoxin C5a and C5a des-Arg through cleavage by the plasminogen activator activity of a human fibrosarcoma cell line. J Biol Chem 1994; 269: 25529–33.Google Scholar
  16. 16.
    Goretzki L, Schmitt M, Mann K et al. Effective activation of the proenzyme form of the urokinase-type plasminogen activator (pro-uPA) by the cysteine protease cathepsin L. FEBS 1992; 1(2): 112–8.Google Scholar
  17. 17.
    Stephens RW, Pöllänen J, Tapiovaara H et al. Activation of prourokinase and plasminogen on human sarcoma cells: A proteolytic system with surface-bound reactants. J Cell Biol 1989; 108: 1987–95.PubMedGoogle Scholar
  18. 18.
    Ellis V, Behrendt N, Danø K. Plasminogen activation by receptor-bound urokinase: A kinetic study with both cell-associated and isolated receptor. J Biol Chem 1991; 266(19): 12752–8.PubMedGoogle Scholar
  19. 19.
    Estreicher A. Muhlhauser J, Carpentier JL et al. The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes. J Cell Biol 1990; 111: 783–92.PubMedGoogle Scholar
  20. 20.
    Yamamoto M, Sawaya R, Mohanam S et al. Expression and localization of urokinase-type plasminogen activator receptor in human gliomas. Cancer Res 1994; 54: 5016–20.PubMedGoogle Scholar
  21. 21.
    Limongi P, Resnati M, Hernandez-Marrero L et al. Biosynthesis and apical localization of the urokinase receptor in polarized MDCK epithelial cells. FEBS Lett 1995; 369: 207–11.PubMedGoogle Scholar
  22. 22.
    Fibbi G, Magnelli L, Pucci M, Del Rosso M. Interaction of urokinase A chain with the receptor of human keratinocytes stimulates release of urokinase-like plasminogen activator. Exp Cell Res 1990; 187: 33–8.PubMedGoogle Scholar
  23. 23.
    Nusrat AR, Chapman HA. An autocrine role for urokinase in phorbol ester-mediated differentiation of myeloid cell lines. J Clin Invest 1991; 87: 1091–7.PubMedGoogle Scholar
  24. 24.
    Dear AE, Costa M, Medcalf RL. Urokinase-mediated transactivation of the plasminogen activator inhibitor type 2 (PAI-2) gene promoter in HT-1080 cells utilizes AP-1 binding sites and potentiates phorbol ester-mediated induction of endogenous PAI-2 mRNA. FEBS Lett 1997; 402: 265–72.PubMedGoogle Scholar
  25. 25.
    Kanse SM, Kost C, Wilhelm OG et al. The urokinase receptor is a major vitronectin-binding protein on endothelial cells. Exp Cell Res 1996; 224: 344–53.PubMedGoogle Scholar
  26. 26.
    Xue W, Mizukami I, Todd RF III, Petty HF. Urokinase-type plasminogen activator receptors associate with β1 and β3 integrins of fibrosarcoma cells: Dependence on extracellular matrix components. Cancer Res 1997; 57: 1682–9.PubMedGoogle Scholar
  27. 27.
    Yebra M, Parry GCN, StrØmblad S et al. Requirement for receptor-bound urokinase-type plasminogen activator for integrin α v β 5-directed cell migration. J Cell Biol 1996; 271: 29393–9.Google Scholar
  28. 28.
    Waltz DA, Natkin LR, Fujita RM et al. Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin. J Clin Invest 1997; 100(1): 58–67.PubMedGoogle Scholar
  29. 29.
    Pyke C, Kristensen P, Ralfkiaer E et al. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am J Pathol 1991; 138: 1059–67.PubMedGoogle Scholar
  30. 30.
    Takahashi K, Ikeo K, Gojobori T, Tanifuji M. Local function of urokinase receptor at the adhesion contact sites of a metastatic tumor cell. Thromb Res 1990; Suppl X, 55–61.Google Scholar
  31. 31.
    Bastholm L, Nielsen MH, De Mey J et al. Confocal fluorescence microscopy of urokinase plasminogen activator receptor and cathepsin D in human MDA-MB-231 breast cancer cells migrating in reconstituted basement membrane. Biotechnic Histochem 1994; 69(2): 61–7.Google Scholar
  32. 32.
    Mizukami IF, Garni-Wagner BA, DeAngelo LM et al. Immunologic detection of the cellular receptor for urokinase plasminogen activator. Clin Immunol Immunopathol 1994; 71(1): 96–104.PubMedGoogle Scholar
  33. 33.
    Buo L, Meling GI, Karlsrud TS et al. Antigen levels of urokinase plasminogen activator and its receptor at the tumor-host interface of colorectal adenocarcinomas are related to tumor aggressiveness. Hum Pathol 1995; 26: 1133–8.PubMedGoogle Scholar
  34. 34.
    Goldfarb RH, Ziche M, Murano GM et al. Plasminogen activators (urokinase) mediate neo-vascularization: Possible role in tumor angiogenesis. Sem Thromb Hem 1986; 12: 337–8.Google Scholar
  35. 35.
    Berman M, Winthrop D, Ausprunk D et al. Plasminogen activator (urokinase) causes vascularization of the cornea. Invest Opthalmol Vis Sci 1982; 22: 191–9.Google Scholar
  36. 36.
    Andreasen PA, Kjøller L, Christensen L, Duffy M. The urokinase-type plasminogen activator system in cancer metastasis: A review. Int J Cancer 1997; 72: 1–22.PubMedGoogle Scholar
  37. 37.
    Mignatti P, Rifkin DB. Plasminogen activators and matrix metalloproteinases in angiogenesis. Enzyme Protein 1996; 49: 117–37.PubMedGoogle Scholar
  38. 38.
    Rabbani SA, Xing RH. Role of urokinase (uPA) and its receptor (uPAR) in invasion and metastasis of hormone-dependent malignancies. Int J Oncol 1998; 12(4): 911–20.PubMedGoogle Scholar
  39. 39.
    Reuning U, Magdolen V, Wilhelm O et al. Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis (Review). Int J Oncol 1998; 13(5): 893–906.PubMedGoogle Scholar
  40. 40.
    Blasi F. uPA, uPAR, PAI-1-a key intersection of proteolytic, adhesive and chemotactic highways? Immunol Today 1997; 18(9): 415–7.PubMedGoogle Scholar
  41. 41.
    Chapman HA. Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration. Curr Opin Cell Biol 1997; 9: 714–24.PubMedGoogle Scholar
  42. 42.
    Ellis V Cellular receptors for plasminogen activators. Trends Cardiovasc Med 1997; 7(7): 227–34.Google Scholar
  43. 43.
    Plesner T, Behrendt N, Ploug M. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR. Stem Cells 1997; 15: 398–408.PubMedCrossRefGoogle Scholar
  44. 44.
    Preissner KT, May AE, Wohn KD et al. Molecular crosstalk between adhesion receptors and proteolytic cascades in vascular remodeling. Thromb Hemost 1997; 78(1): 88–95.Google Scholar
  45. 45.
    Schmitt M, Harbeck N, Thomssen C et al. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: Prognostic relevance and target for therapy. Thromb Hemost 1997; 78(1): 285–96.Google Scholar
  46. 46.
    Tapiovaara H, Alitalo R, Vaheri A. Plasminogen activation on tumor cell surfaces and its involvement in human leukemia. Adv Cancer Res 1996; 69: 101–33.PubMedGoogle Scholar
  47. 47.
    Henkin J. Proteases and metastasis. Ann Rep Med Chem 1993; 28: 151–60.Google Scholar
  48. 48.
    Brunner G, Simon MM, Kramer MD. Activation of pro-urokinase by the human T cell-associated serine proteinase HuTSP-1. FEBS Lett 1990; 260(1): 141–4.PubMedGoogle Scholar
  49. 49.
    Stack MS, Johnson DA. Human mast cell tryptase activates single-chain urinary-type plasminogen activator (pro-urokinase). J Biol Chem 1994; 269(13): 9416–9.PubMedGoogle Scholar
  50. 50.
    Mazar AP, Buko A, Petros AM et al. Domain analysis of urokinase plasminogen activator (uPA): preparation and characterization of intact A-chain molecules. Fibrinolysis 1992; 6(Suppl 1): 49–55.Google Scholar
  51. 51.
    Harris RJ, Leonard CK, Guzzetta AW, Spellman MW. Tissue plasminogen activator has an O-linked fucose attached to threonine-61 in the epidermal growth factor domain. Biochemistry 1991; 30: 2311–4.PubMedGoogle Scholar
  52. 52.
    Harris RJ, Spellman MW. O-linked fucose and other post-translational modifications unique to EGF modules. Glycobiology 1993; 3(3): 219–24.PubMedGoogle Scholar
  53. 53.
    Rabbani SA, Mazar AP, Bernier SM et al. Structural requirements for the growth factor activity of the amino-terminal domain of urokinase. J Biol Chem 1992; 267: 14151–6.PubMedGoogle Scholar
  54. 54.
    Nusrat AR, Mazar AP, Henkin J, Chapman HA. A role for urokinase in mediating phorbol ester induced macrophages-like maturation and adhesion of U937 and other myeloid cells. Fibrinolysis 1992; 6(Suppl 1): 71–6.Google Scholar
  55. 55.
    Hansen AP, Petros AM, Meadows RP et al. Solution structure of the amino-terminal fragment of urokinase-type plasminogen activator. Biochemistry 1994; 33: 4847–64.PubMedGoogle Scholar
  56. 56.
    Franco P, Iaccarino C, Chirardonna F et al. Phosphorylation of human pro-urokinase on Ser138/303 impairs its receptor-dependent ability to promote myelomonocytic adherence and motility. J Cell Biol 1997; 137(3): 777–91.Google Scholar
  57. 57.
    Franco P, Massa O, Garcia-Rocha M et al. Protein kinase C-dependent in vivo phosphorylation of prourokinase leads to the formation of a receptor competitive antagonist. J Biol Chem 1998; 42: 27734–40.Google Scholar
  58. 58.
    Mizukami IF, Todd III RF. A soluble form of the urokinase plasminogen activator receptor (suPAR) can bind to hematopoietic cells. J Leukocyte Biol 1998; 64: 203–13.PubMedGoogle Scholar
  59. 59.
    Kanse SM, Benzakour O, Kanthou C et al. Induction of vascular SMC proliferation by urokinase indicates a novel mechanism of action in vasoproliferative disorders. Arterioscler Thromb Vasc Biol 1997; 17(11): 2848–54.PubMedGoogle Scholar
  60. 60.
    Dong-Le Bourhis X, Lambrecht V, Boilly B. Transforming growth factor beta 1 and sodium butyrate differentially modulate urokinase plasminogen activator and plasminogen activator inhibitor-1 in human breast normal and cancer cells. Br J Cancer 1998; 77(3): 396–403.PubMedGoogle Scholar
  61. 61.
    Hildenbrand R, Jansen C, Wolf G et al. Transforming growth factor-β stimulates urokinase expression in tumor-associated macrophages of the breast. Lab Invest 1998; 78(1): 59–71.PubMedGoogle Scholar
  62. 62.
    Plow EF, Herren T, Redlitz A et al. The cell biology of the plasmin system. FASEB J 1995; 9: 939–45.PubMedGoogle Scholar
  63. 63.
    Behrendt N, Rønne E, Danø K. The structure and function of the urokinase receptor, a membrane protein governing plasminogen activation on the cell surface. Biol Chem Hoppe-Seyler 1992; 376: 269–79.Google Scholar
  64. 64.
    Mandriota SJ, Seghezzi G, Vassalli JD et al. Vascular endothelial growth factor increases urokinase receptor expression in vascular endothelial cells. J Biol Chem 1995; 270(17): 9709–16.PubMedGoogle Scholar
  65. 65.
    Mandriota SJ, Pepper MS. Vascular endothelial growth factor-induced in vitro angiogenesis and plasminogen activator expression are dependent on endogenous basic fibroblast growth factor. J Cell Sci 1997; 110: 2293–302.PubMedGoogle Scholar
  66. 66.
    Pepper MS, Sappino AP, Stöcklin R et al. Upregulation of urokinase receptor expression on migrating endothelial cells. J Cell Biol 1993; 122(3): 673–84.PubMedGoogle Scholar
  67. 67.
    Blasi F, Conese M, Møller N et al. The urokinase receptor: Structure, regulation and inhibitor-mediated internalization. Fibrinolysis 1994; 8(1): 182–8.Google Scholar
  68. 68.
    Conese M, Blasi F. Urokinase/Urokinase receptor system: Internalization/degradation of urokinase-serpin complexes: Mechanism and regulation. Biol Chem Hoppe-Seyler 1995; 376: 143–55.PubMedGoogle Scholar
  69. 69.
    Møller LB, Ploug M, Blasi F. Structural requirements for glycosyl-phosphatidylinositol-anchor attachment in the cellular receptor for urokinase plasminogen activator. Eur J Biochem 1992; 208: 493–500.PubMedGoogle Scholar
  70. 70.
    Ploug M, Behrendt N, Løber D, Danø K. Protein structure and membrane anchorage of the cellular receptor for urokinase-type plasminogen activator. Thromb Hemo 1991; 17(3): 183–93.CrossRefGoogle Scholar
  71. 71.
    Ploug M, Ellis V. Structure-function relationships in the receptor for urokinase-type plasminogen activator. FEBS Lett 1994; 349: 163–8.PubMedGoogle Scholar
  72. 72.
    Rosse WF. Paroxysmal nocturnal hemoglobinuria: the biochemical defects and the clinical syndrome. Blood Rev 1989; 3: 192–200.PubMedGoogle Scholar
  73. 73.
    Vassalli JD. The urokinase receptor. Fibrinolysis 1994; 8(Suppl 1): 172–81.Google Scholar
  74. 74.
    Pöllänen JJ. The N-terminal domain of human urokinase receptor contains two distinct regions critical for ligand recognition. Blood 1993; 82(9): 2719–29.PubMedGoogle Scholar
  75. 75.
    Ploug M, Rahbek-Nielsen H, Ellis V, Roepstorff P, Danø K. Chemical modification of the urokinase-type plasminogen activator and its receptor using tetranitromethane. Evidence for the involvement of specific tyrosine residues in both molecules during receptor-ligand interaction. Biochem 1995; 34: 12524–34.Google Scholar
  76. 76.
    Behrendt N, Ronne E, Danø K. Domain interplay in the urokinase receptor. J Biol Chem 1996; 271(37): 22885–94.PubMedGoogle Scholar
  77. 77.
    Higazi AAR, Mazar A, Wang J et al. Soluble human urokinase receptor is composed of two active units. J Biol Chem 1997; 272(8): 5348–53.PubMedGoogle Scholar
  78. 78.
    Oda M, Shiraishi A, Hasegawa M. Analysis of the ternary complex formation of human urokinase with the separated two domains of its receptor. Eur J Biochem 1998; 256: 411–8.PubMedGoogle Scholar
  79. 79.
    Ploug M, Østergaard S, Hansen LB et al. Photoaffinity labeling of the human receptor for urokinase-type plasminogen activator using a decapeptide antagonist. Evidence for a composite ligand-binding site and a short interdomain separation. Biochemistry 1998; 37(11): 3612–22.PubMedGoogle Scholar
  80. 80.
    Riittinen L, Limongi P, Crippa MP et al. Removal of domain D2 or D3 of the human urokinase receptor does not affect ligand affinity. FEBS Lett 1996; 381: 1–6.PubMedGoogle Scholar
  81. 81.
    Higazi A.AR, Upson RH, Cohen RL et al. Interaction of single-chain urokinase with its receptor induces the appearance and disappearance of binding epitopes within the resultant complex to other cell surface proteins. Blood 1996b; 88(2): 542–51.PubMedGoogle Scholar
  82. 82.
    Waltz DA, Chapman HA. Reversible cellular adhesion to vitronectin linked to urokinase receptor occupancy. J Biol Chem 1994; 269: 14746–51.PubMedGoogle Scholar
  83. 83.
    Quax PHA, van Leeuwen RTJ, Verspaget HW, Verheijen JH. Protein and messenger RNA levels of plasminogen activators and inhibitors analyzed in 22 human tumor cell lines. Cancer Res 1990; 50: 1488–94.PubMedGoogle Scholar
  84. 84.
    Resnati M, Guttinger M, Valcamonica S et al. Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J 1996; 15(7): 1572–82.PubMedGoogle Scholar
  85. 85.
    Hoyer-Hansen G, Ploug M, Behrendt N et al. Cell-surface acceleration of urokinase-catalyzed receptor cleavage. Eur J Biochem 1997; 243: 21–6.PubMedGoogle Scholar
  86. 86.
    Fazioli F, Resnati M, Sidenius N et al. A urokinase-sensitive region of the human urokinase receptor is responsible for its chemotactic activity. EMBO J 1997; 16(24): 7279–86.PubMedGoogle Scholar
  87. 87.
    Solberg H, Romer J, Holm A et al. A cleaved form of the receptor of urokinase-type plasminogen activator in invasive transplanted human and murine tumors. Int J Cancer 1994; 58: 877–81.PubMedGoogle Scholar
  88. 88.
    Hoyer-Hansen G, Behrendt N, Ploug M et al. The intact urokinase receptor is required for efficient vitronectin binding: Receptor cleavage prevents ligand interaction. FEBS Lett 1997; 420: 79–85.PubMedGoogle Scholar
  89. 89.
    Anichini E, Zamperini A, Chevanne M et al. Interaction of urokinase-type plasminogen activator with its receptor rapidly induces activation of glucose transporters. Biochemistry 1997; 36: 3076–83.PubMedGoogle Scholar
  90. 90.
    Rabbani SA, Gladu J, Mazar AP et al. Induction in human osteoblastic cells (SaOS2) of the early response genes fos, jun, and myc by the amino terminal fragment (ATF) of urokinase. J Cell Physiol 1997; 172: 137–45.PubMedGoogle Scholar
  91. 91.
    Dumler I, Weis A, Mayboroda OA et al. The Jak/Stat pathway and urokinase receptor signaling in human aortic vascular smooth muscle cells. J Biol Chem 1998; 273(1): 315–21.PubMedGoogle Scholar
  92. 92.
    Koshelnick Y, Ehart M, Hufnagl P et al. Urokinase receptor is associated with the components of the JAK1/STAT1 signaling pathway and leads to activation of this pathway upon receptor clustering in the human kidney epithelial tumor cell line TCL-598. J Biol Chem 1997; 272(45): 28563–7.PubMedGoogle Scholar
  93. 93.
    Stahl A, Mueller BM. The urokinase-type plasminogen activator receptor, a GPI-linked protein, is localized in calveolae. J Cell Biol 1995; 129: 335–44.PubMedGoogle Scholar
  94. 94.
    Busso N, Masur SK, Dazega D et al. Induction of cell migration by pro-urokinase binding to its receptor: possible mechanism for signal transduction in human epithelial cells. J Cell Biol 1994; 126(1): 259–70.PubMedGoogle Scholar
  95. 95.
    Bohuslav J, Horejsi V, Hansmann C et al. Urokinase plasminogen activator receptor, β2-integrins, and Src-kinases within a single receptor complex of human monocytes. J Exp Med 1995; 181: 1381–90.PubMedGoogle Scholar
  96. 96.
    May AE, Kanse SM, Lund LR et al. Urokinase receptor (CD87) regulates leukocyte recruitment via β 2 integrins in vivo. J Exp Med 1998; 188(6): 1029–37.PubMedGoogle Scholar
  97. 97.
    Wei Y, Lukashev M, Simon DI et al. Regulation of integrin function by the urokinase receptor. Science 1996; 273: 1551–5.PubMedGoogle Scholar
  98. 98.
    Chavakis T, Kanse SM, Yutzy B et al. Vitronectin concentrates proteolytic activity on the cell surface and extracellular matrix by trapping soluble urokinase receptor-urokinase complexes. Blood 1998; 91(7): 2305–12.PubMedGoogle Scholar
  99. 99.
    Deng G, Curriden SA, Wang S et al. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J Cell Biol 1996; 134(6): 1563–71.PubMedGoogle Scholar
  100. 100.
    Wei Y, Waltz DA, Rao N et al. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem 1994; 269: 32380–8.PubMedGoogle Scholar
  101. 101.
    Carriero MV, Del Vecchio S, Franco P et al. Vitronectin binding to urokinase receptor in human breast cancer. Clin Cancer Res 1997; 3: 1299–308.PubMedGoogle Scholar
  102. 102.
    Kjøller L, Kanse SM, Kirkegaard T et al. Plasminogen activator inhibitor-1 represses integrin-and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activator. Exp Cell Res 1997; 232: 420–9.PubMedGoogle Scholar
  103. 103.
    Stahl A, Mueller BM. Melanoma cell migration on vitronectin: Regulation by components of the plasminogen activation system. Int J Cancer 1997; 71: 116–22.PubMedGoogle Scholar
  104. 104.
    Gyetko MR, Todd III RF, Wilkinson CC, Sitrin RG. The urokinase receptor is required for human monocyte chemotaxis in vitro. J Clin Invest 1994; 93: 1380–7.PubMedGoogle Scholar
  105. 105.
    Gyetko MR, Sitrin RG, Fuller JA et al. Function of the urokinase receptor (CD87) in neutrophil chemotaxis. J Leuk Biol 1995; 58: 533–8.Google Scholar
  106. 106.
    Sitrin RG, Todd RF, Petty HR et al. The urokinase receptor (CD87) facilitates CD11/CD18-mediated adhesion of human monocytes. J Clin Invest 1996; 97(8): 1942–51.PubMedGoogle Scholar
  107. 107.
    Wong WSF, Simon DI, Rosoff PM et al. Mechanism of pertussis toxin-induced myelomonocytic cell adhesion: Role of Mac-1 (CD11b/CD18) and urokinase receptor (CD87). Immunology 1996; 88: 90–7.PubMedGoogle Scholar
  108. 108.
    Nip J, Rabbani SA, Shibata HR, Brodt P. Coordinated expression of the vitronectin receptor and the urokinase-type plasminogen activator receptor in metastatic melanoma cells. J Clin Invest 1995; 95: 2096–103.PubMedGoogle Scholar
  109. 109.
    Wilcox SA, Reho T, Higgins PJ et al. Localization of urokinase to focal adhesions by human fibrosarcoma cells synthesizing recombinant vitronectin. Biochem Cell Biol 1996; 74: 899–910.PubMedCrossRefGoogle Scholar
  110. 110.
    Planus E, Barlovatz-Meimon G, Rogers RA et al. Binding of urokinase to plasminogen activator inhibitor type-1 mediates cell adhesion and spreading. J Cell Sci 1997; 110(9): 1091–8.PubMedGoogle Scholar
  111. 111.
    Nguyen DH, Hussaini IM, Gonias SL. Binding of urokinase-type plasminogen activator to its receptor in MCF-7 cells activates extracellular signal-regulated kinase 1 and 2 which is required for increased cellular motility. J Biol Chem 1998; 273(14): 8502–7.PubMedGoogle Scholar
  112. 112.
    Ossowski L, Reich E. Antibodies to plasminogen activator inhibit human tumor metastasis. Cell 1983; 35: 611–9.PubMedGoogle Scholar
  113. 113.
    Behrendt N, Ronne E, Ploug M et al. The human receptor for urokinase plasminogen activator. J Biol Chem 1990; 265: 6453–60.PubMedGoogle Scholar
  114. 114.
    Roldan AL, Cubellis MV, Masucci MT et al. Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. EMBO J 1990; 9(2): 467–74.PubMedGoogle Scholar
  115. 115.
    Rao NK, Shi GP, Chapman HA. Urokinase receptor is a multifunctional protein: Influence of receptor occupancy on macrophages gene expression. J Clin Invest 1995; 96: 465–74.PubMedGoogle Scholar
  116. 116.
    Mars WM, Kim TH, Stolz DB et al. Presence of urokinase in serum-free primary hepatocyte cultures and its role in activating hepatocyte growth factor. Cancer Res 1996; 56: 2837–43.PubMedGoogle Scholar
  117. 117.
    Pannell R, Gurewich V. Activation of plasminogen by single-chain urokinase or by two-chain urokinase-A demonstration that single-chain urokinase has a low catalytic activity (pro-urokinase). Blood 1987; 69(1): 22–6.PubMedGoogle Scholar
  118. 118.
    Higazi AAR, Cohen RL, Henkin J et al. Enhancement of the enzymatic activity of single-chain urokinase plasminogen activator by soluble urokinase receptor. J Biol Chem 1995; 270(29): 17375–80.PubMedGoogle Scholar
  119. 119.
    Manchanda N, Schwartz BS. Single chain urokinase. Augmentation of enzymatic activity upon binding to monocytes. J Biol Chem 1991; 266(22): 12752–8.Google Scholar
  120. 120.
    Schwartz BS. Differential inhibition of soluble and cell surface receptor-bound single-chain urokinase by plasminogen activator inhibitor type 2. J Biol Chem 1994; 269(11): 8319–23.PubMedGoogle Scholar
  121. 121.
    Higazi AR, Mazar A, Wang J et al. Single-chain urokinase-type plasminogen activator bound to its receptor is relatively resistant to plasminogen activator inhibitor type 1. Blood 1996a; 87(9): 3545–9.PubMedGoogle Scholar
  122. 122.
    Ellis V. Functional analysis of the cellular receptor for urokinase in plasminogen activation. J Biol Chem 1996; 271(25): 14779–84.PubMedGoogle Scholar
  123. 123.
    Behrendt N, Danø K. Effect of purified, soluble urokinase receptor on the plasminogen-pro-urokinase activation system. FEBS lett 1996; 393: 31–6.PubMedGoogle Scholar
  124. 124.
    Behrendt N, Danø K. Reply to comment on Effect of purified, soluble urokinase receptor on the plasminogen-prourokinase activation system (A.A-R. Higazi). FEBS lett 1997; 402: 293–4.PubMedGoogle Scholar
  125. 125.
    Wang J, Mazar A, Quan N, Schneider A, Henkin J. Plasminogen activation by pro-urokinase in complex with its receptor: Dependence on a tri-peptide (Spectrozyme Pl). Eur J Biochem 1997; 247(1): 256–61.PubMedGoogle Scholar
  126. 126.
    Bacharach E, Itin A, Keshet E. Apposition-dependent induction of plasminogen activator inhibitor type 1 expression: A mechanism for balancing pericellular proteolysis during angiogenesis. Blood 1998; 92(3): 939–45.PubMedGoogle Scholar
  127. 127.
    Goldfarb RH, Kitson RP, Brunson KW. Biology of cancer metastases. Hematogenous dissemination. In Lotze MT, Rubin JT (eds): Regional Therapy of Advanced Cancer. Philadelphia: Lippincott-Raven 1997; 1–9.Google Scholar
  128. 128.
    Goldfarb RH, Timonen T, Herbermann RB. Production of plasminogen activator by human natural killer cells, large granular lymphocytes. J Exp Med 1985; 159: 935–51.Google Scholar
  129. 129.
    Carpen O, Saksela O, Saksela E. Identification and localization of urokinase-type plasminogen activator in human NK cells. Int J Cancer 1986; 38: 355–60.PubMedGoogle Scholar
  130. 130.
    Jones CM, Taraemlli D, Clouse CA, Goldfarb RH. Role of bacterial lipopolysaccharide and lymphokine in the regulation of macrophage activation: Correlates between secretion of plasminogen activator and tumor lysis. Immunobiol 1984; 166: 410–27.Google Scholar
  131. 131.
    Hasegawa T, Soreneson L, Dohi M et al. Induction of urokinase-type plasminogen activator receptor by IL-1β. Am J Cell Mol Biol 1997; 16: 683–92.Google Scholar
  132. 132.
    Hildenbrand R, Dilger I, Hørlin A, Stutte HJ. Urokinase and macrophages in tumour angiogenesis. Br J Cancer 1995; 72: 818–23.PubMedGoogle Scholar
  133. 133.
    Yoshida E, Tsichiya K, Sugiki M et al. Modulation of the receptor for urokinase-type plasminogen activator in macrophages-like cells by inflammatory mediators. Inflammation 1996; 20(3): 319–26.PubMedGoogle Scholar
  134. 134.
    Sunderkoötter C, Steinbrink K, Goebeler M et al. Macrophages and angiogenesis. J Leukocyte Biol 1994; 55: 410–22.Google Scholar
  135. 135.
    Whiteside TL, Goldfarb RH. Antitumor effector cells: Extravasation and control of metastasis. In Goldfarb RH, Whiteside TL (eds): Tumor Immunology and Cancer Therapy. New York: Marcel Dekker 1994; 159–73.Google Scholar
  136. 136.
    Goldfarb RH. NK cells: Adhesive interactions, microvasculature, extracellular matrices and angiogenesis. Nat Immun 1997; 15: 71–163.Google Scholar
  137. 137.
    Kitson RP, Appasamy PM, Nannmark U et al. Matrix metalloproteinases produced by rat IL-2 activated NK cells. J Immunol 1998; 160: 4248–53.PubMedGoogle Scholar
  138. 138.
    Wainberg MA, Israel E, Margolese RG. Further studies on the mitogenic and immune-modulating effects of plasminogen activator. Immunol 1982; 45: 715–20.Google Scholar
  139. 139.
    Sundar SK, Bergeron J, Menezes J. Purified plasminogen activating factor produced by malignant lymphoid cells abrogates lymphocyte cytotoxicity. Clin Exp Immunol 1984; 56: 701–8.PubMedGoogle Scholar
  140. 140.
    Arras M, Ito WD, Scholz D et al. Monocyte activation in angiogenesis and collateral growth in the rabbit hindlimb. J Clin Invest 1998; 101(1): 40–50.PubMedGoogle Scholar
  141. 141.
    Lewis CE, Leek R, Harris A, McGee J. Cytokine regulation of angiogenesis in breast cancer: The role of tumor-associated macrophages. J Leukocyte Biol 1995; 57: 747–51.PubMedGoogle Scholar
  142. 142.
    Fontan PA, Amura CR, Sordelli DO. Treatment with a non-steroidal anti-inflammatory agent delays the growth of spontaneous pulmonary metastases of a mammary adenocarcinoma of non-detected immunogenicity. Br J Cancer 1992; 66: 800–4.PubMedGoogle Scholar
  143. 143.
    Szekanecz Z, Haines GK, Koch AE. Differential expression of the urokinase receptor (CD87) in arthritic and normal synovial tissues. J Clin Pathol 1997; 50: 314–9.PubMedGoogle Scholar
  144. 144.
    Ando Y, Jensen PJ. Protein kinase C mediates up-regulation of urokinase and its receptor in the migrating keratinocytes of wounded cultures, but urokinase is not required for movement across a substratum in vitro. J Cell Physiol 1996; 167(3): 500–11.PubMedGoogle Scholar
  145. 145.
    Bechtel MJ, Reinartz J, Rox JM et al. Upregulation of cell-surface associated plasminogen activation in cultured keratinocytes by interleukin-1β and tumor necrosis factor-α. Exp Cell Res 1996; 223: 395–404.PubMedGoogle Scholar
  146. 146.
    Martins-Green M, Boudreau N, Bissell MJ. Inflammation is responsible for the development of wound-induced tumors in chickens infected with Rous Sarcoma Virus. Cancer Res 1994; 54: 4334–41.PubMedGoogle Scholar
  147. 147.
    Mars WM, Zarnegar R, Michalopoulos GK. Activation of hepatocyte growth factor by the plasminogen activators uPA and tPA. Am J Pathol 1993; 143: 949–58.PubMedGoogle Scholar
  148. 148.
    Naldini L, Vigna E, Bardelli A et al. Biological activation of pro-HGF (hepatocyte growth factor) by urokinase is controlled by a stoichiometric reaction. J Biol Chem 1995; 270: 603–11.PubMedGoogle Scholar
  149. 149.
    Mignatti P, Mazzieri R, Rifkin DB. Expression of the urokinase receptor in vascular endothelial cells is stimulated by basic fibroblast growth factor. J Cell Biol 1991; 113(5): 1193–201.PubMedGoogle Scholar
  150. 150.
    Jeffers M, Rong S, Vande Woude GF. Hepatocyte growth factor/scatter factor-met signaling in tumorigenicity and invasion/metastasis. J Mol Med 1996; 74: 505–13.PubMedGoogle Scholar
  151. 151.
    Nykjær A, Conese M, Christensen EI et al. Recycling of the urokinase receptor upon internalization of the uPA:serpin complexes. EMBO J 1997; 16(10): 2610–20.PubMedGoogle Scholar
  152. 152.
    Nykjaer A, Christensen EI, Vorum H et al. Mannose 6-phosphate/insulin-like growth factor-II receptor targets the urokinase receptor to lysosomes via a novel binding interaction. J Cell Biol 1998; 141(3): 815–28.PubMedGoogle Scholar
  153. 153.
    Gualandris A, Conejo TL, Giunciuglio D et al. Urokinase-type plasminogen activator overexpression enhances the invasive capacity of endothelial cells. Microvasc Res 1997; 53: 254–60.PubMedGoogle Scholar
  154. 154.
    Olofsson B, Korpelainen E, Pepper MS et al. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc Natl Acad Sci USA 1998; 95: 11709–14.PubMedGoogle Scholar
  155. 155.
    Graham CH, Fitzpatrick TE, McCrae KR. Hypoxia stimulates urokinase receptor expression through a heme protein-dependent pathway. Blood 1998; 91(9): 3300–7.PubMedGoogle Scholar
  156. 156.
    Lu H, Mabilat C, Yeh P et al. Blockage of urokinase receptor reduces in vitro the motility and the deformability of endothelial cells. FEBS Lett 1996; 380: 21–4.PubMedGoogle Scholar
  157. 157.
    Min HY, Doyle LV, Vitt CR et al. Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. Cancer Res 1996; 56(10): 2428–33.PubMedGoogle Scholar
  158. 158.
    Schnaper HW, Barnathan ES, Mazar A et al. Plasminogen activators augment endothelial cell organization in vitro by two distinct pathways. J Cell Physiol 1995; 165: 107–18.PubMedGoogle Scholar
  159. 159.
    Koolwijk P, Van Erck MGM, De Vree WJA et al. Cooperative effect of TNFα, bFGF, and VEGF on the formation of tubular structures of human microvascular endothelial cells in a fibrin matrix. Role of urokinase activity. J Cell Biol 1996; 132(6): 1177–88.PubMedGoogle Scholar
  160. 160.
    Lansink M, Koolwijk P, Van Hinsbergh V, Kooistra T. Effect of steroid hormone and retinoids on the formation of capillary-like tubular structures of human microvascular endothelial cells in fibrin matrices is related to urokinase expression. Blood 1998; 92(3): 927–38.PubMedGoogle Scholar
  161. 161.
    Sato Y, Morimoto A, Kiue A et al. Irsogladine is a potent inhibitor of angiogenesis. FEBS Lett 1993; 322: 155–8.PubMedGoogle Scholar
  162. 162.
    Ren CJ, Ueda F, Roses DF et al. Irsogladine maleate inhibits angiogenesis in wild-type and plasminogen activator-deficient mice. J Surg Res 1998; 77: 126–31.PubMedGoogle Scholar
  163. 163.
    Odekon LE, Sato Y, Rifkin DB. Urokinase-type plasminogen activator mediates basic fibroblast growth factor-induced bovine endothelial cell migration independent of its proteolytic activity. J Cell Physiol 1992; 150: 258–63.PubMedGoogle Scholar
  164. 164.
    Dubois-Stringfellow N, Jonczyk A, Bautch VL. Perturbations in the fibrinolytic pathway abolish cyst formation but not capillary-like organization of cultured murine endothelial cells. Blood 1994; 33(11): 3206–17.Google Scholar
  165. 165.
    Pepper MS, Mandriotta SJ, Jeltsch M et al. Vascular endothelial growth factor (VEGF)-C synergizes with basic fibroblast growth factor and VEGF in the induction of angiogenesis in vitro and alters endothelial cell extracellular proteolytic activity. J Cell Physiol 1998; 177(3): 439–52.PubMedGoogle Scholar
  166. 166.
    Maehara Y, Hasuda S, Abe T et al. Tumor angiogenesis and micrometastasis in bone marrow of patients with early gastric cancer. Clin Cancer Res 1998; 4: 2129–34.PubMedGoogle Scholar
  167. 167.
    Bajou K, Noel A, Gerard RD et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med 1998; 4(8): 923–8.PubMedGoogle Scholar
  168. 168.
    Carmeliet P, Moons L, Lijnen R et al. Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation. A gene targeting and gene transfer study in mice. Circulation 1997; 96: 3180–91.PubMedGoogle Scholar
  169. 169.
    Foekens JA, Look MP, Peters HA et al. Urokinase-type plasminogen activator and its inhibitor PAI-1: Predictors of poor response to Tamoxifen therapy in recurrent breast cancer. JNCI 1995; 87: 751–6.PubMedGoogle Scholar
  170. 170.
    Ishikawa H, Satoh H, Kamma H et al. The effect of TNP-470 on cell proliferation and urokinase-type plasminogen activator and its inhibitor in human lung cancer cell lines. J Exp Ther Oncol 1996; 1(6): 390–6.PubMedGoogle Scholar
  171. 171.
    Shoji M, Hancock WW, Abe K et al. Activation of coagulation and angiogenesis in cancer. Immunohistochemical localization in situ of clotting proteins and vascular endothelial growth factor in human cancer. Am J Pathol 1998; 152(2): 399–411.PubMedGoogle Scholar
  172. 172.
    Zhang Y, Deng Y, Luther T et al. Tissue factor controls the balance of angiogenic and anti-angiogenic properties of tumor cells in mice. J Clin Invest 1994; 94: 1320–7.PubMedCrossRefGoogle Scholar
  173. 173.
    Roberts AB, Sporn MB, Assoian RK et al. Transforming growth factor β: Rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci 1986; 83: 4167–71.PubMedGoogle Scholar
  174. 174.
    Berse B, Hunt JA, Diegel RJ et al. Hypoxia augments cytokine (transforming growth factor-β (TGF-β) and IL-1)-induced vascular endothelial growth factor secretion by human synovial fibroblasts. Clin Exp Immunol 1999; 115(1): 176–82.PubMedGoogle Scholar
  175. 175.
    Taniguchi T, Kakkar AK, Tuddenham EG et al. Enhanced expression of urokinase receptor induced through the tissue factor-factor VIIa pathway in human pancreatic cancer. Cancer Res 1998; 58(19): 4461–7.PubMedGoogle Scholar
  176. 176.
    Thompson WD, Campbell R, Evans T. Fibrin degradation and angiogenesis: Quantitative analysis of the angiogenic response in the chick chorioallantoic membrane. J Pathol 1985; 145(1): 27–37.PubMedGoogle Scholar
  177. 177.
    Tang H, Kerins DM, Hao Q et al. The urokinase-type plasminogen activator receptor mediates tyrosine phosphorylation of focal adhesion proteins and activation of mitogen-activated protein kinase in cultured endothelial cells. J Biol Chem 1998; 273(29): 18268–72.PubMedGoogle Scholar
  178. 178.
    Fibbi G, Caldini R, Chevanne M et al. Urokinase-dependent angiogenesis in vitro and diacylglycerol production are blocked by antisense oligonucleotides against the urokinase receptor. Lab Invest 1998; 78(9): 1109–19.PubMedGoogle Scholar
  179. 179.
    Nakata S, Ito K-I, Fujimori M et al. Involvement of vascular endothelial growth factor and urokinase-type plasminogen activator receptor in microvessel invasion in human colorectal cancers. Int J Cancer 1998; 79: 179–86.PubMedGoogle Scholar
  180. 180.
    Hildenbrand R, Glienke W, Magdolen V et al. Urokinase receptor localization in breast cancer and benign lesions assessed by in situ hybridization and immunohistochemistry. Histochem Cell Biol 1998; 110(1): 27–32.PubMedGoogle Scholar
  181. 181.
    Carmeliet P, Moons L, Dewerchin M et al. Receptor-independent role of urokinase-type plasminogen activator in pericellular plasmin and matrix metalloproteinase proteolysis during vascular wound healing in mice. J Cell Biol 1998; 140(1): 233–45.PubMedGoogle Scholar
  182. 182.
    Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular permeability, and angiogenesis. Am J Pathol 1995; 146: 1029–39.PubMedGoogle Scholar
  183. 183.
    Carmeliet P, Collen D. Vascular development and disorders: molecular analysis and pathogenetic insights. Kidney Int 1998; 53: 1519–49.PubMedGoogle Scholar
  184. 184.
    Shapiro RL, Duquette JG, Roses DF et al. Induction of primary cutaneous melanocytic neoplasms in urokinase-type plasminogen activator (uPA)-deficient and wild-type mice: cellular blue nevi invade but do not progress to malignant melanoma in uPA-deficient animals. Cancer Res 1996; 56: 3597–604.PubMedGoogle Scholar
  185. 185.
    Bugge TH, Kombrinck KW, Xiao Q et al. Growth and dissemination of Lewis lung carcinoma in plasminogen-deficient mice. Blood 1997; 90: 4522–31.PubMedGoogle Scholar
  186. 186.
    Sabapathy KT, Pepper MS, Kiefer F et al. Polyoma middle-T induced vascular tumor formation: The role of the plasminogen activator/plasmin system. J Cell Biol 1997; 137: 953–63.PubMedGoogle Scholar
  187. 187.
    Shioda T, Munn LL, Fenner MH et al. Early events of metastasis in the microcirculation involve changes in gene expression of cancer cells. Am J Pathol 1997; 150: 2099–112.PubMedGoogle Scholar
  188. 188.
    Gohji K, Nakajima M, Boyd D et al. Organ-site dependence for the production of urokinase-type plasminogen activator and metastasis by human renal cell carcinoma cells. Am J Pathol 1997; 151: 1655–61.PubMedGoogle Scholar
  189. 189.
    Kobayashi H, Gotoh J, Shinohara H et al. Inhibition of the metastasis of Lewis lung carcinoma by antibody against urokinase-type plasminogen activator in the experimental and spontaneous metastasis model. Thromb Haemost 1994; 71: 474–80.PubMedGoogle Scholar
  190. 190.
    Mandler R, Rimoldi D, Karikó K, Samid D. Urokinase-type plasminogen activator in experimental metastasis of human osteosarcoma cells. Cancer J 1991; 4: 316–21.Google Scholar
  191. 191.
    Crowley CW, Cohen RL, Lucas BK et al. Prevention of metastasis by inhibition of the urokinase receptor. Proc Natl Acad Sci USA 1993; 90: 5021–5.PubMedGoogle Scholar
  192. 192.
    Astedt B, Billstrom A, Lecander I. Urokinase-producing tumor growth in SCID mice inhibited by recombinant PAI-2. Fibrinolysis 1995; 9: 175–7.Google Scholar
  193. 193.
    Achbarou A, Kaiser S, Trembly G et al. Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. Cancer Res 1994; 54: 2372–7.PubMedGoogle Scholar
  194. 194.
    Evans DM, Sloan-Stakleff K, Arvan M, Guyton DP. Time and dose dependency of the suppression of pulmonary metastases of rat mammary cancer by amiloride. Clin Exp Met 1998; 16: 353–7.Google Scholar
  195. 195.
    Haeckel C, Krueger S, Roessner A. Antisense inhibition of urokinase: effect on malignancy in a human osteosarcoma cell line. Int J Cancer 1998; 77: 153–60.PubMedGoogle Scholar
  196. 196.
    Rabbani SA, Harakidas P, Davidson DJ et al. Prevention of prostate-cancer metastasis in vivo by a novel synthetic inhibitor of urokinase-type plasminogen activator (uPA). Int J Cancer 1995; 63: 840–5.PubMedGoogle Scholar
  197. 197.
    Xing RH, Mazar A, Henkin J, Rabbani SA. Prevention of breast cancer growth, invasion, and metastasis by antiestrogen Tamoxifen alone or in combination with urokinase inhibitor, B-428. Cancer Res 1997; 57: 3585–93.PubMedGoogle Scholar
  198. 198.
    Towle MJ, Lee A, Maduakor EC et al. Inhibition of urokinase by 4-substituted benzo[b]-2-carboxamidines: an important new class of selective synthetic urokinase inhibitor. Cancer Res 1993; 53: 2553–9.PubMedGoogle Scholar
  199. 199.
    Go Y, Chintala SK, Mahanam S et al. Inhibition of in vivo tumorigenicity and invasiveness of a human glioblastoma cell line transfected with antisense uPAR vectors. Clin Exp Metastasis 1997; 15: 440–6.PubMedGoogle Scholar
  200. 200.
    Yu W, Kim J, Ossowski L. Reduction in surface urokinase receptor forces malignant cells into a protracted state of dormancy. J Cell Biol 1997; 137: 767–77.PubMedGoogle Scholar
  201. 201.
    Kobayashi H, Gotoh J, Fujie M et al. Inhibition of metastasis of Lewis Lung carcinoma by a synthetic peptide within the growth factor-like domain of urokinase in the experimental and spontaneous metastasis model. Int J Cancer 1994; 57: 727–33.PubMedGoogle Scholar
  202. 202.
    Li H, Griscelli F, Opolon P et al. Adenovirus-mediated delivery of a uPA/uPAR antagonist suppresses angiogenesis-dependent tumor growth and dissemination in mice. Gene Ther 1998; 1105–13.Google Scholar
  203. 203.
    Heiss MM, Algayer H, Gruetzner KU et al. Individual development and uPA-receptor expression of disseminated tumour cells in bone marrow: A reference to early systemic disease in solid cancer. Nat Med 1995; 1(10): 1035–9.PubMedGoogle Scholar
  204. 204.
    Kim J, Yu W, Kovalski K, Ossowski L. Requirement for specific proteases in cancer cell intravasation as revealed by a novel semiquantitative PCR-based assay. Cell 1998; 94: 353–62.PubMedGoogle Scholar
  205. 205.
    Fowler B, Mackman N, Parmer RJ, Miles LA. Binding of human single chain urokinase to Chinese hamster ovary cells and cloning of hamster uPAR. Thromb Hemost 1998; 80: 148–54.Google Scholar
  206. 206.
    Vassalli J-D, Belin D. Amiloride selectively inhibits the urokinase-type plasminogen activator. FEBS Lett 1987; 214: 187–91.PubMedGoogle Scholar
  207. 207.
    Jankun J, Keck RW, Skrzypczak-Jankun E, Swiercz R. Inhibitors of urokinase reduce size of prostate cancer xenografts in severe combined immunodeficient mice. Cancer Res 1997; 57: 559–63.PubMedGoogle Scholar
  208. 208.
    Yang H, Henkin J, Kim KH, Greer J. Selective inhibition of urokinase by substituted phenylguanidines: Quantitative structure-activity relationship analyses. J Med Chem 1990; 33: 2956–61.PubMedGoogle Scholar
  209. 209.
    Geratz JD, Shaver SR, Tidwell RR. Inhibitory effect of amidino-substituted heterocyclic compounds on the amidase activity of plasmin and high and low molecular weight urokinase and on urokinase-induced plasminogen activation. Thromb Res 1981; 24: 73–83.PubMedGoogle Scholar
  210. 210.
    Alonso DF, Farias EF, Ladeda V et al. Effects of synthetic urokinase inhibitors on local invasion and metastasis in a murine mammary tumor model. Breast Cancer Res Treat 1996; 40: 209–23.PubMedGoogle Scholar
  211. 211.
    Wakselman M, Xie J, Mazaleyrat J-P. New mechanism-based inactivators of trypsin-like proteinases. Selective inactivation of urokinase by functionalized cyclopeptides incorporating a sulfoniomethyl-substituted m-aminobenzoic acid residue. J Med Chem 1993; 36: 1539–47.PubMedGoogle Scholar
  212. 212.
    Kawada M, Umezawa K. Suppression of in vitro invasion of human fibrosarcoma cells by a leupeptin analogue inhibiting the urokinase-plasmin system. Biochem Biophys Res Comm 1993; 209(1): 25–30.Google Scholar
  213. 213.
    Ke S-H, Coombs GS, Tachias T et al. Optimal subsite occupancy and design of a selective inhibitor of urokinase. J Biol Chem 1997; 272(33): 20456–62.PubMedGoogle Scholar
  214. 214.
    Spraggon G, Phillips C, Nowak UK et al. The crystal-structure of the catalytic domain of human urokinase-type plasminogen activator. Structure 1995; 3: 681–91.PubMedGoogle Scholar
  215. 215.
    Appella E, Robinson EA, Ullrich SJ et al. The receptor-binding sequence of urokinase: A biological function for the growth-factor module of proteases. J Biol Chem 1987; 262(10): 4437–40.PubMedGoogle Scholar
  216. 216.
    Burgle M, Koppitz M, Riemer C et al. Inhibition of the interaction of urokinase plasminogen activator (uPA) with its receptor (uPAR) by synthetic peptides. Biol Chem Hoppe-Seyler 1997; 378: 231–7.Google Scholar
  217. 217.
    Goodson RJ, Doyle MV, Kaufman SE, Rosenberg S. High-affinity urokinase receptor antagonists identified with bacteriophage peptide display. Proc Natl Acad Sci 1994; 91(15): 7129–33.PubMedGoogle Scholar
  218. 218.
    Del Rosso M, Fibbi G, Pucci M, Matucci C. Antisense oligonucleotides against the urokinase receptor: A therapeutic strategy for the control of cell invasion in rheumatoid arthritis and cancer. Clin Exp Rheumatol 1998; 389–93.Google Scholar
  219. 219.
    Eisenbrand G, Lauck-Birkel S, Wang WC. An approach toward more selective anticancer agents. Synthesis Oct 1996; 1246–58.Google Scholar
  220. 220.
    Mauceri HJ, Hanna NN, Beckett MA et al. Combined effects of angiostatin and ionizing radiation in antitumor therapy. Nature 1998; 394: 287–91.PubMedGoogle Scholar
  221. 221.
    D'Angelo G, Struman I, Martial J, Weiner RI. Activation of mitogen-activated protein kinases by vascular endothelial growth factor and basic fibroblast growth factor in capillary endothelial cells is inhibited by the anti-angiogenic factor 16-kDa N-terminal fragment of prolactin. Proc Natl Acad Sci 1995; 92(14): 6374–8.PubMedGoogle Scholar
  222. 222.
    Jones MK, Sarfeh IJ, Tarnawski AS. Induction of in vitro angiogenesis in the endothelial-derived cell line, EA hy926, by ethanol is mediated through PKC and MAPK. Biochem Biophys Res Commun 1998; 249(1): 118–23.PubMedGoogle Scholar
  223. 223.
    Tsujii M, Kawano S, Tsuji S et al. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998; 93(5): 705–16.PubMedGoogle Scholar
  224. 224.
    Levenson AS, Kwaan HC, Svoboda KM et al. Oestradiol regulation of the components of the plasminogen-plasmin system in MDA-MB-231 human breast cancer cells stably expressing the oestrogen receptor. Br J Cancer 1998; 78(1): 88–95.PubMedGoogle Scholar
  225. 225.
    Jain RK, Safabakhsh N, Sckell A et al. Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: Role of vascular endothelial growth factor. Proc Natl Acad Sci 1998; 95: 10820–5.PubMedGoogle Scholar
  226. 226.
    O'Reilly M, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 1996; 2(6): 689–92.PubMedGoogle Scholar
  227. 227.
    Dong Z, Kumar R, Yang X, Fidler IJ. Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis Lung Carcinoma. Cell 1997; 88: 801–10.PubMedGoogle Scholar
  228. 228.
    Gately S, Twardowski P, Stack SS et al. The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin. Proc Natl Acad Sci 1997; 94: 10868–72.PubMedGoogle Scholar
  229. 229.
    O'Mahony CA, Albo D, Tuszynski GP, Berger DH. Transforming growth factor-β1 inhibits generation of angiostatin by human pancreatic cancer cells. Surgery 1998; 124(2): 388–93.PubMedGoogle Scholar
  230. 230.
    Ji WR, Castellino FJ, Chang Y et al. Characterization of kringle domains of angiostatin as antagonists of endothelial cell migration, an important process in angiogenesis. FASEB J 1998; 12(15): 1731–8.PubMedGoogle Scholar
  231. 231.
    Claesson-Welsh L, Welsh M, Ito N et al. Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD. Proc Natl Acad Sci 1998; 95(10): 5579–83.PubMedGoogle Scholar
  232. 232.
    Cao Y, Chen A, An SSA et al. Kringle 5 of plasminogen is a novel inhibitor of endothelial cell growth. J Biol Chem 1997; 272(36): 22924–8.PubMedGoogle Scholar
  233. 233.
    Ji WR, Barrientos LG, Llinas M et al. Selective inhibition by kringle 5 of human plasminogen on endothelial cell migration, an important process in angiogenesis. Biochem Biophys Res Comm 1998; 247: 414–9.PubMedGoogle Scholar
  234. 234.
    Leibovich SJ, Polverini PJ, Shepard HM, Wiseman DM, Shively V, Nuseir N. Macrophage-induced angiogenesis is mediated by tumour necrosis factor-alpha. Nature 1987; 329: 630–2.PubMedGoogle Scholar
  235. 235.
    Pepper MS, Ferrara N, Orci L, Montesano R. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commun 1992; 189: 824–31.PubMedGoogle Scholar
  236. 236.
    van Hinsbergh VW, van den Berg EA, Fiers W, Dooijewaard G. Tumor necrosis factor induces the production of urokinase-type plasminogen activator by human endothelial cells. Blood 1990; 75: 1991–8.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1999

Authors and Affiliations

  • Andrew P. Mazar
    • 1
  • Jack Henkin
    • 2
  • Ronald H. Goldfarb
    • 3
  1. 1.Department of Tumor BiologyÅngstrom PharmaceuticalsSan DiegoUSA
  2. 2.Abbott LaboratoriesPharmaceutical Products Division, D48RAbbott ParkUSA
  3. 3.Department of Molecular Biology and Immunology and Institute for Cancer ResearchThe University of North Texas Health Sciences Center at Fort WorthFort WorthUSA

Personalised recommendations